Epigenomics AG reaffirmed revenue guidance for the full year 2022. For the period, the company revenue forecast remains unchanged between EUR 0.3 million to EUR 0.8 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 EUR | -.--% | +8.31% | -.--% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.19% | 11.52B | |
+44.16% | 3.27B | |
-19.90% | 2.02B | |
-38.37% | 2.03B | |
-30.21% | 1.44B | |
+16.18% | 1.01B | |
-6.11% | 719M | |
-32.75% | 418M | |
-52.35% | 339M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
- News Epigenomics AG
- Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022